Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0313
Abstract: Most primary immunodeficiency diseases, and select secondary immunodeficiency diseases, are treated with immunoglobulin (IG) therapy, administered intravenously or subcutaneously (SCIG). The first instance of IG replacement for primary immunodeficiency disease was a 16.5% formulation administered… read more here.
Keywords: overview subcutaneous; immunodeficiency diseases; secondary immunodeficiency; immunodeficiency ... See more keywords